Regal Assets Analytics

SanaCurrents’ speculative report on Aptinyx’s (APTX) phase II trial of NYX-2925 fibromyalgia

By |2022-06-27T08:48:05-04:00June 25th, 2022|Tags: |

Aptinyx Inc. (NASDAQ:APTX) Probability Sentiment SUMMARY Aptinyx, Inc. (NASDAQ:APTX) listed four years ago on the [...]

SanaCurrents on Prometheus’ (RXDX) precision medicine approach in ulcerative colitis & Crohn’s disease

By |2022-06-13T19:47:36-04:00June 12th, 2022|Tags: |

Prometheus Biosciences, Inc. (NASDAQ:RXDX) Probability Sentiment SUMMARY Early-stage investors continue to back new drugs for [...]

SanaCurrents on Rani’s (RANI) transformative RaniPill to deliver large molecule biologics

By |2022-06-06T00:47:00-04:00June 6th, 2022|Tags: |

$RANI Probability Sentiment Needles. Who enjoys needles? No one. If someone claims indifference to regular [...]

SanaCurrents Portfolio Update: APLS files NDA, IMUX UC drug falters in phase II topline, plus VERA and ACET

By |2022-06-13T19:48:07-04:00June 5th, 2022|Tags: , , , |

Apellis Pharmaceuticals (NASDAQ:APLS) on June 1 submitted an NDA for its drug pegcetacoplan to be approved to treat geographic atrophy [...]

SanaCurrents on FDA decision for uniQure’s (QURE) gene therapy to treat hemophilia B

By |2022-05-31T07:33:34-04:00May 31st, 2022|Tags: |

uniqure N.v. (NASDAQ:QURE) Probability Sentiment SUMMARY The inherited bleeding disorder hemophilia remains a lucrative rare [...]

SanaCurrents on Insmed’s (INSM) entry in pulmonary arterial hypertension (PAH)

By |2022-05-18T13:37:33-04:00May 7th, 2022|Tags: |

Insmed, Inc. (NASDAQ:INSM) Probability Sentiment SUMMARY Pulmonary arterial hypertension (PAH) comprises a group of severe [...]

Go to Top